Problems at Seer Inc (SEER)
Problems at Seer Inc (SEER)
Problems at Seer Inc (SEER)
Seer Inc (NASDAQ: SEER — $2.26 billion) describes itself as “a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality.” The company may be more bark than bite.
Seer appears to have misled investors about its recent Chinese distribution partnership, customer base, and even its management’s past track record. In addition, since its December 2020 IPO, Seer has disclosed the departures of its Chief Operating Officer, Chief Medical Officer, and Chief Busines Officer. Seer’s CEO also has a part-time role as executive chair of a recently launched SPAC.
Founded in March 2018, Seer competes in the hot field of proteomics – protein measurement to help detect potential health problems. Below is the company’s representation of its in-development product suite:
On its Q2 earnings c…